A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

May 31, 2015

Conditions
Multiple Sclerosis
Interventions
DRUG

Interferon β-1a

"Sterile preservative-free solution packaged in graduated pre-filled syringes~Subcutaneous injection~Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®"

DRUG

Teriflunomide

"Film-coated tablet~Oral administration"

Trial Locations (54)

1070

Investigational Site Number 056003, Brussels

1083

Investigational Site Number 348001, Budapest

1096

Investigational Site Number 348005, Budapest

1106

Investigational Site Number 348003, Budapest

2500

Investigational Site Number 348002, Esztergom

5000

Investigational Site Number 788002, Monastir

6000

Investigational Site Number 348007, Kecskemét

8200

Investigational Site Number 348004, Veszprém

9000

Investigational Site Number 056001, Ghent

9007

Investigational Site Number 756002, Sankt Gallen

10034

Investigational Site Number 203003, Prague

10117

Investigational Site Number 276011, Berlin

10126

Investigational Site Number 380006, Torino

11527

Investigational Site Number 300001, Athens

12099

Investigational Site Number 276012, Berlin

12808

Investigational Site Number 203002, Prague

16132

Investigational Site Number 380007, Genova

20132

Investigational Site Number 380001, Milan

27100

Investigational Site Number 380004, Pavia

28222

Investigational Site Number 724002, Majadahonda

30120

Investigational Site Number 724003, Murcia

30559

Investigational Site Number 276010, Hanover

33076

Investigational Site Number 250003, Bordeaux

34000

Investigational Site Number 250001, Montpellier

44791

Investigational Site Number 276001, Bochum

45138

Investigational Site Number 276006, Essen

48013

Investigational Site Number 724001, Bilbao

48149

Investigational Site Number 276002, Münster

55131

Investigational Site Number 276009, Mainz

58633

Investigational Site Number 203004, Jihlava

59037

Investigational Site Number 250004, Lille

60020

Investigational Site Number 380010, Ancona

63003

Investigational Site Number 250005, Clermont-Ferrand

64711

Investigational Site Number 276007, Erbach im Odenwald

67091

Investigational Site Number 250002, Strasbourg

70124

Investigational Site Number 380005, Bari

90015

Investigational Site Number 380003, Cefalù

97980

Investigational Site Number 276003, Bad Mergentheim

B-3590

Investigational Site Number 056002, Hasselt

G6V 3Z1

Investigational Site Number 124003, Lévis

N6A 5A5

Investigational Site Number 124002, London

A1B 3V6

Investigational Site Number 124004, St. John's

01307

Investigational Site Number 276005, Dresden

06120

Investigational Site Number 276004, Halle

Unknown

Investigational Site Number 300002, Thessaloniki

09126

Investigational Site Number 380008, Cagliari

00185

Investigational Site Number 380002, Roma

15-276

Investigational Site Number 616002, Bialystok

80-803

Investigational Site Number 616004, Gdansk

20-718

Investigational Site Number 616003, Lublin

02-957

Investigational Site Number 616001, Warsaw

08036

Investigational Site Number 724007, Barcelona

SW17 0QT

Investigational Site Number 826002, London

PL6 5BX

Investigational Site Number 826003, Plymouth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY